Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.

Article Details

Citation
Copy to clipboard

Tran P, Hanna I, Eggimann FK, Schoepfer J, Ray T, Zhu B, Wang L, Priess P, Tian X, Hourcade-Potelleret F, Einolf HJ

Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.

Xenobiotica. 2020 Feb;50(2):150-169. doi: 10.1080/00498254.2019.1594449. Epub 2019 May 6.

PubMed ID
31006307 [ View in PubMed
]
Abstract

Asciminib is a potent, specific BCR-ABL1 inhibitor being developed for the treatment of patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL).Here, we present the results of human oral absorption, distribution, metabolism, excretion (ADME) and in vitro studies that together provide an overall understanding of the metabolism, distribution and clearance of asciminib in humans.Asciminib was rapidly absorbed with a maximum plasma concentration at two hours post-dose. Total radioactivity and asciminib showed similar terminal half-lives in plasma.Oral asciminib absorption ranged between a minimum of 33%, and a maximum of 57% based on the metabolite profiles of late time-point feces collections.Asciminib was eliminated mainly through feces via unchanged asciminib excretion and metabolism.Direct glucuronidation and oxidation were major metabolic pathways in human that were catalyzed predominantly by UDP-glucuronosyltransferase (UGT)2B7 and cytochrome P450 (CYP)3A4, respectively.The relative contribution of the glucuronidation pathway to the total clearance of asciminib via metabolism is estimated to range approximately 28-58%, whereas the relative contribution of the oxidative pathway is estimated to range approximately 37-64%, based upon the maximum oral absorption in humans.

DrugBank Data that Cites this Article

Drugs